Chapter 17 of 25
- Check kidney function and overall fitness
- Coordinate radiation, cisplatin and brachytherapy
- Consider additional therapy only for eligible settings
- Monitor toxicity and avoid unnecessary delays
What you will learn
Understand cisplatin fitness and monitoring; distinguish alternative strategies; recognize the specific setting for immunotherapy with radiation.
The treatment backbone
External-beam radiation treats the tumour region and appropriate lymph nodes; brachytherapy delivers the concentrated internal dose. Cisplatin is commonly given during radiation as a radiosensitizer. This is different from chemotherapy alone for widespread disease. Exact schedules, doses and supportive medicines belong to the treating team, not a patient-facing calculator.
Before treatment, clinicians assess kidney function, blood counts, hearing, neuropathy, hydration, performance status and other illnesses. Obstruction of urine flow may need treatment first. Cisplatin can injure kidneys, affect hearing or nerves, and cause nausea or electrolyte changes. Hydration, anti-nausea medicines and repeated blood tests reduce risk and guide adjustments.
If cisplatin is unsuitable
A clinician may consider carboplatin in selected patients who cannot safely receive cisplatin, but evidence is less extensive and it should not be described as automatically equivalent. Some patients need radiation without concurrent chemotherapy because medical risks outweigh benefit. Maintaining high-quality radiotherapy and brachytherapy remains central.
Report reduced urine output, persistent vomiting, tingling, hearing changes, fever or inability to drink promptly. Do not force a fixed fluid volume if heart or kidney disease limits intake; obtain an individualized hydration plan. Dose changes are safety decisions, not evidence that the patient has failed treatment.
Pembrolizumab with definitive treatment
KEYNOTE-A18 studied previously untreated high-risk locally advanced disease: FIGO 2014 IB2–IIB with positive nodes or III–IVA. Pembrolizumab or placebo was added during chemoradiation and continued afterward. The trial demonstrated improved outcomes, but the study population and an approved indication are not interchangeable.
The verified US FDA indication is pembrolizumab with chemoradiotherapy for FIGO 2014 stage III–IVA disease; this setting does not require PD-L1 CPS positivity. A FIGO 2018 IIIC label alone does not automatically establish the older stage required by the indication. Other countries' labels, funding and access must be checked locally. Immune-related toxicity adds monitoring needs, and brachytherapy remains necessary.
Induction and additional chemotherapy
INTERLACE compared six weekly cycles of carboplatin/paclitaxel before standard chemoradiation with chemoradiation alone in 500 eligible patients. At five years, overall survival was 80% versus 72% and progression-free survival 72% versus 64%. This supports a specific induction strategy in appropriately selected patients and centres able to transition promptly to radiation. It does not establish that any chemotherapy schedule before radiation is helpful.
INTERLACE and KEYNOTE-A18 studied different strategies and populations. Combining induction chemotherapy and pembrolizumab with chemoradiation is not automatically proven by either trial. OUTBACK did not show an overall-survival benefit from routinely adding carboplatin/paclitaxel after standard chemoradiation. More treatment can increase harm without improving outcomes.
Misconception and common question
“Locally advanced means incurable” is false: many patients receive treatment intended to cure. Can chemotherapy replace brachytherapy? No. Each component has a different role, and adding medicines does not compensate for inadequate local treatment.
Take-home messages
Ask about treatment intent, cisplatin suitability and brachytherapy timing. Understand the named evidence behind an added drug. Avoid unnecessary delays while reporting toxicity promptly.
References and review status
- Lorusso et al. KEYNOTE-A18 overall survival analysis, Lancet 2024
- FDA — Pembrolizumab with chemoradiotherapy, FIGO 2014 III–IVA, January 2024
- McCormack et al. INTERLACE randomized phase III trial, Lancet 2024
- Mileshkin et al. OUTBACK randomized phase III trial, Lancet Oncology 2023
- Cibula et al. ESGO/ESTRO/ESP cervical cancer guidelines, 2023 update
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy